Clinical trial
Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous…
NCT00072579 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00072579 |
|---|---|
| Title | Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment |
| Official title | Phase II Study of GM-CSF in Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) Who Are Not in Complete Cytogenetic Remission After Initial Therapy |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | sargramostim |
| Start date | May 1, 2003 |
| Primary completion | Apr 1, 2006 |
| Completion | Dec 1, 2007 |
| First posted | Nov 5, 2003 |
| Last update posted | Jan 19, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: